Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Raining on the parade even more, Pfizer just reported some good news that seems to confirm the presence of some internal issues. So let's examine this new green flag that's also a red flag for anyone ...

Cash runway is not expected to get Intellia to meaningful data readouts for their Phase III trials. See why NTLA stock is a ...

Revelation: Pfizer’s Dangerous Knowledge About COVID-19 Vaccine Risks** New evidence is surfacing that suggests Pfizer was well aware of serious adverse events linked to its C ...

3. The agency also approved Hympavzi (marstacimab, Pfizer) as routine prophylaxis to prevent or reduce the frequency of ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

WELL, TIS THE SEASON FOR SICKNESS, STOMACH VIRUSES, FLU AND COVID CASES POPPING UP IN YOUNG AND OLD ALIKE. BUT THOSE LOOKING FOR MEDICATION TO TREAT THE CORONAVIRUS ARE FEELING STICKER SHOCK. WVTM 13 ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage biopharma announced Monday. In a study that tested the highest dosage of ...

Reports of drug-related supply-chain issues were 40 percent less likely to result in drug shortages in Canada versus the United States, according to a new study.

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...